Welcome to our dedicated page for Carecloud SEC filings (Ticker: CCLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CareCloud, Inc. (CCLD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed healthcare technology company with common stock (CCLD) and 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock (CCLDO), CareCloud uses SEC filings to report material events, financial results, acquisitions, and capital structure updates.
Investors can review current reports on Form 8-K that describe significant developments such as quarterly earnings releases, preferred stock dividend declarations, acquisitions, and governance matters. For example, recent 8-K filings have covered the announcement of preferred stock dividend payments, the acquisition of Medsphere Systems Corporation and related financial statements, the acquisition of HFMA’s MAP App, and notices regarding Nasdaq listing rule compliance following changes in board composition.
Filings also document financial performance and guidance. Earnings-related 8-Ks incorporate press releases that discuss revenue, profitability, adjusted EBITDA, and management’s expectations, while accompanying exhibits may include presentation slides and non-GAAP reconciliations. These materials help investors understand how CareCloud’s AI-driven and technology-enabled solutions, acquisitions, and operational initiatives affect its financial results.
CareCloud’s SEC disclosures further address preferred stock terms and dividends, including details on its 8.75% Series A and Series B Cumulative Redeemable Perpetual Preferred Stock. Filings and exhibits describe dividend rates, payment schedules, redemption provisions, and, in the case of Series A, events such as mandatory conversion and delisting from Nasdaq when that series no longer met continued listing requirements.
On Stock Titan, AI-powered tools can summarize lengthy filings and highlight key points, such as changes in revenue guidance, acquisition impacts, or updates on preferred dividend plans. Users can quickly scan new 8-Ks, 10-Qs, and 10-Ks as they become available from EDGAR, while also tracking any Form 4 insider transaction reports that may be filed. This page is designed to help readers interpret CareCloud’s regulatory history and stay informed about how corporate actions, acquisitions, AI initiatives, and capital decisions are reflected in its official SEC record.
CareCloud, Inc. filed a current report describing a change to its corporate bylaws. On April 2, 2026, the Board of Directors approved and adopted Amended and Restated Bylaws, effective immediately, revising the quorum requirement for meetings of stockholders. The full text of the amended bylaws is provided as an exhibit to the report.
CareCloud, Inc. reported a board change affecting its audit committee. On March 24, 2026, the board appointed Cameron Munter to serve as a member of the Audit Committee. The board determined he meets Nasdaq’s independence requirements, so the Audit Committee now has three independent directors and the company has regained compliance with Nasdaq Listing Rule 5605(c)(2). Nasdaq has notified the company that it is back in compliance with this rule.
CareCloud, Inc. reports a material cybersecurity incident involving its CareCloud Health division. On March 16, 2026, a temporary network disruption affected 1 of its 6 electronic health record environments for about eight hours until functionality and data access were fully restored that evening.
The incident, believed to be caused by an unauthorized third party, appears contained to the CareCloud Health environment. CareCloud engaged a Big Four cyber response team, notified its cybersecurity insurer, and reported the matter to law enforcement. The company is still determining whether, and to what extent, patient information or other data was accessed or exfiltrated.
CareCloud states that, as of this report, the incident has not had a material impact on operations and is not reasonably likely to have a material impact on its financial condition or results of operations. It nevertheless deems the incident material due to the sensitivity of potentially affected data and potential remediation, legal, regulatory, notification, and reputational consequences.
CareCloud, Inc. files its annual report describing its technology-enabled revenue cycle management, cloud software and expanding generative AI solutions for U.S. healthcare providers. The company relies heavily on offshore operations in Pakistan and Sri Lanka, where roughly 3,300 staff support its cost advantage.
As of June 30, 2025, non‑affiliate common equity had an aggregate market value of about $85.1 million, and at March 6, 2026 there were 42,492,949 common shares outstanding. The filing highlights extensive business, cybersecurity, regulatory and macro risks, including past suspension and later resumption of preferred dividends, ongoing arrears, and dilution from a March 2025 conversion of most Series A preferred into common stock.
CareCloud, Inc. filed a current report describing several updates. The company issued an earnings press release and an accompanying slide presentation on March 12, 2026, which are included as exhibits and provide details on its recent operating and financial performance.
On March 10, 2026, director A. Hadi Chaudhry resigned from the Board, effective immediately. His resignation is intended to help the company regain compliance with Nasdaq Listing Rule 5605, which requires a majority-independent board. The company states his departure did not arise from any disagreement over operations, policies, or practices.
CareCloud director Lawrence S. Sharnak reported an equity award vesting and share issuance. On February 8, 2026, 7,500 restricted stock units converted into 7,500 shares of CareCloud common stock at a price of $0. According to the filing, these restricted stock units and the resulting shares were granted under the company’s Amended and Restated Equity Incentive Plan without payment by Sharnak.
Following the transaction, Sharnak directly owned 127,750 shares of common stock and 26,250 restricted stock units. This reflects routine compensation-related activity rather than an open-market purchase or sale.
CareCloud, Inc. director Cameron Munter reported a routine equity compensation vesting. On February 8, 2026, 7,500 restricted stock units converted into 7,500 shares of common stock at a price of $0 per share, under the company’s Amended and Restated Equity Incentive Plan.
After this conversion, Munter directly beneficially owned 202,750 shares of CareCloud common stock and 26,250 restricted stock units. The transaction involved no cash payment by the reporting person and reflects standard compensation-based vesting rather than an open‑market purchase or sale.
CareCloud, Inc. director Anne Busquet reported the vesting and conversion of 7,500 restricted stock units into common stock on February 8, 2026. The RSUs and resulting shares were issued under the company’s Amended and Restated Equity Incentive Plan without any cash payment by her.
After this equity award vesting, she directly holds 295,138 shares of CareCloud common stock and 26,250 derivative securities in the form of restricted stock units.
CareCloud, Inc. director Bill Korn reported the vesting and conversion of 7,500 restricted stock units into common stock on February 8, 2026. The RSUs and resulting shares were issued under the company’s Amended and Restated Equity Incentive Plan without any cash payment by Korn.
After this transaction, Korn beneficially owns 211,633 shares of CareCloud common stock directly and 26,250 restricted stock units, reflecting his ongoing equity-based compensation as a director.
CareCloud, Inc. director Bill Korn reported the vesting of equity awards and related share issuance. On January 31, 2026, 6,250 restricted stock units converted into 6,250 shares of common stock at a price of $0.00 under the company’s Amended and Restated Equity Incentive Plan, without payment by Korn. Following this transaction, he directly owned 204,133 shares of common stock and 33,750 restricted stock units.